Epic Sciences and Genomic Health, Inc. today announced that a local Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final local coverage determination (LCD) for the Oncotype DX® AR-V7 Nucleus Detect™ test.
The final LCD recommends Medicare coverage for use of the Oncotype CX AR-V7 Nucleus Test becomes effective on December 10, 2018, throughout the United States.
The test can be used to help determine which men with metastatic castrate resistant prostate cancer (mCRPC) may benefit from continued the second line androgen receptor signaling inhibitor (ARSi) therapy, such as enzalutamide (Xtandi), abiraterone (Zytiga) and apalutamide (Erleada), as well as those who are resistant who may benefit from chemotherapy.
There is another AR-V7 test being tested at Johns Hopkins, however this test is neither approved nor will its use be covered by Medicare.
Joel T Nowak
